A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis.

BACKGROUND & AIMS Overt hepatic encephalopathy (HE) affects patients' quantity and quality of life and places a burden on families. There is evidence that overt HE might be prevented pharmacologically, but prophylaxis would be justified and cost effective only for patients at risk. We aimed to identify patients with cirrhosis at risk for overt HE. METHODS We collected data from October 2009 through December 2012 for 216 consecutive patients with cirrhosis (based on liver biopsy, 96 patients with minimal HE), admitted to the Gastroenterology Unit at the University of Rome. Patients were followed up and evaluated for an average of 14.7 ± 11.6 months; development of overt HE was recorded. We analyzed end-stage liver disease scores, shunt placement, previous overt or minimal HE, psychometric hepatic encephalopathy score (PHES), and levels of albumin, bilirubin, creatinine, and sodium to develop a prediction model. We validated the model in 112 patients with cirrhosis seen at the University of Padua and followed up for 12 ± 9.5 months. RESULTS During the follow-up period, 68 patients (32%) developed at least 1 episode of overt HE. Based on multivariate analysis, the development of overt HE was associated with previous HE, minimal HE (based on PHES), and level of albumin less than 3.5 g/dL (area under curve [AUC], 0.74). A model that excluded minimal HE but included albumin level and previous HE also identified patients who would develop overt HE (AUC, 0.71); this difference in AUC values was not statistically significant (P = .104). Both models were validated in the independent group of patients (3 variables: AUC, 0.74; 95% confidence interval, 0.66-0.83; and 2 variables: AUC, 0.71; 95% confidence interval, 0.63-0.78). CONCLUSIONS We developed and validated a model to identify patients with cirrhosis at risk for overt HE based on previous HE, albumin levels, and PHES. If PHES was not available, previous HE and albumin levels still can identify patients at risk. Psychometric evaluation is essential for patients with no history of HE. These findings should aid in planning studies of pharmacologic prevention of overt HE.

[1]  M. Merli,et al.  Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). , 1996, Hepatology.

[2]  M. Pavesi,et al.  Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). , 2014, Journal of hepatology.

[3]  P. Bisiacchi,et al.  Improving the inhibitory control task to detect minimal hepatic encephalopathy. , 2010, Gastroenterology.

[4]  C. Moy,et al.  The Albumin in Acute Stroke Part 1 Trial: An Exploratory Efficacy Analysis , 2011, Stroke.

[5]  L. Seeff,et al.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. , 1977, Gastroenterology.

[6]  C. Leevy,et al.  Rifaximin treatment in hepatic encephalopathy. , 2010, The New England journal of medicine.

[7]  B. Sharma,et al.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. , 2009, Gastroenterology.

[8]  R. Jalan,et al.  Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications , 2013, Hepatology.

[9]  D. Häussinger,et al.  Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. , 2014, Gastroenterology.

[10]  F. Schliess,et al.  Pathogenetic mechanisms of hepatic encephalopathy , 2008, Gut.

[11]  A. Sanyal,et al.  The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers , 2011, The American Journal of Gastroenterology.

[12]  Manuel Romero-Gómez,et al.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy , 2001, American Journal of Gastroenterology.

[13]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[14]  Alessio Farcomeni,et al.  Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts , 2008, The American Journal of Gastroenterology.

[15]  J. Bajaj,et al.  Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  Fernando Anaya,et al.  Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. , 2009, Drug news & perspectives.

[17]  N. Accornero,et al.  High prevalence of spontaneous portal‐systemic shunts in persistent hepatic encephalopathy: A case‐control study , 2005, Hepatology.

[18]  M. Merli,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. , 2012, Clinics in liver disease.

[19]  A. Sanyal,et al.  Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study , 2011, Alimentary pharmacology & therapeutics.

[20]  B. Sharma,et al.  Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose , 2012, Journal of gastroenterology and hepatology.

[21]  Daniela Mapelli,et al.  Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. , 2008, Journal of hepatology.

[22]  M. Merli,et al.  Does malnutrition affect survival in cirrhosis? , 1996 .

[23]  M. Merli,et al.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. , 2005, Journal of hepatology.

[24]  V. Arroyo,et al.  Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[25]  M. Merli,et al.  Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[27]  R. Jalan,et al.  Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. , 2004, Clinical science.

[28]  Roger Williams,et al.  Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality , 2009, Hepatology.

[29]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[30]  J. Roberts,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. , 1995, The American journal of gastroenterology.

[31]  M. Navasa,et al.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis. , 1999, Journal of hepatology.

[32]  M. Merli,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt , 1996, Digestive Diseases and Sciences.

[33]  Persistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy , 2014 .

[34]  M. Merli,et al.  Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study , 2012, Metabolic Brain Disease.

[35]  G. Toffolo,et al.  Electroencephalography in patients with cirrhosis. , 2011, Gastroenterology.

[36]  R. Butterworth,et al.  Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement , 2011, Alimentary pharmacology & therapeutics.